Lung Cancer Market Size and CAGR by 2031
The Lung Cancer Market is expected to register a CAGR of 8.5% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by Diagnostic (Test, Technology); Therapeutic (Disease Type, Molecule Type). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Lung Cancer Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Lung Cancer Market Segmentation
Diagnostic- Test
- Technology
- Disease Type
- Molecule Type
Strategic Insights
Lung Cancer Market Growth Drivers- Rising Incidence and Prevalence: Part of the reason for the growth of this market is the increasing incidence of lung cancer in patients worldwide. Smoking, environmental pollution, and even occupational hazards, such as exposure to diesel exhaust among truck drivers and heavy equipment handlers, all play a part in that rising tide. When those cases continue to go up, the pressure for appropriate treatments also continues to go up.
- Advancements in Treatment Options: Targeted therapies, in combination with immunotherapies, are revolutionizing the approach to the treatment of lung cancers. The characterization of oncogenic drivers in lung cancers makes the treatment possible to be tailored for specific patients and more effective as targeted treatments. Precision medicine is thus a strong market driver and is pushing the demand for particular therapies and improved outcomes for patients.
- Growing Awareness and Screening Programs: The mounting awareness of lung cancer and its risk factors has led to the establishment of screening and early detection programs. With enhanced early-stage disease detection, the survival rates after therapy are better, and higher demand is seen in society for different treatment modalities. There is also a constant requirement for public health education campaigns and creating an awareness drive to take up screening.
- Shift Towards Personalized Medicine: Now, the most significant trend is personalized medicine, more so in the treatment of non-small cell lung cancer. There appears to be development in targeted therapy, wherein genetic profiling leads to tailored treatment, like treatment plans that make the most of the best outcome for the patients. This development is further supported by research into the molecular characteristics that define lung tumors that continue to date.
- Emergence of Liquid Biopsies: The use of liquid biopsies is increasingly more common as a part of a diagnostic and follow-up protocol for lung cancer by non-invasive methods. Liquid biopsies can detect circulating tumor DNA in blood samples. This would be particularly useful in the attempts to shed light on the dynamics of the tumor and how it is responding to treatment. The market for liquid biopsies is likely going to expand more remarkably with the improvement of technology and technology advancement.
- Increased Focus on Screening Programs: Screening for lung cancer is emerging as an essential feature so that early-stage lung cancers can be identified in patients. The advanced screening programs for high-risk individuals will further improve the survival rate. Thus, there would be growth in the market for lung cancer screening since proper treatment depends strictly on early diagnosis.
- Regulatory Support and Funding: They come in the form of increased research funding and supportive regulatory approaches for lung cancer. Organizations like the Lung Cancer Research Foundation and governmental initiatives provide grants and funding for researching new treatments and novel technologies, eventually providing the necessary money for new therapies as well as access to existing ones.
- Integration of Digital Health Solutions: Integration of digital health technology, which includes telemedicine and mobile health applications, will also offer opportunities in the care of lung cancer. These technological aspects can facilitate engagement, remote monitoring, and easier access to care for patients in underserved areas. Companies offering innovative, customized digital solutions for managing lung cancer are likely to attract that new market interest.
- Collaboration and Partnerships: A potential partnership between a pharmaceutical company, institutions conducting research, and healthcare providers may lead the way toward new treatment protocols and clinical trials. This type of collaboration can help speed up the entry of new treatments into the market in partnerships whereby all the parties pool resources for the advancement of research in lung cancer. This will then improve the profit margins of the parties involved.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Lung Cancer Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Lung Cancer Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The technology segment accounts for highest revenue in product the Lung Cancer Market in 2023
Quest Diagnostics, AstraZeneca, GlaxoSmithKline, Eli Lilly, F Hoffmann La, Roche Ltd, Siemens, Healthcare GmbH accounting for higesh market shares and are some of the major players operating in the market
Asia Pacific region dominated the Lung Cancer Market in 2023
North America region dominated the Lung Cancer Market in 2023
The Lung Cancer Market is estimated to witness a CAGR of 8.5% from 2023 to 2031
The major factors driving the Lung Cancer Market are:
1.Rising Incidence and Prevalence
2.Advancements in Treatment Options
3. Growing Awareness and Screening Programs
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Lung Cancer Market - By Diagnostic
1.3.2 Lung Cancer Market - By Therapeutic
1.3.3 Lung Cancer Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LUNG CANCER MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LUNG CANCER MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. LUNG CANCER MARKET - GLOBAL MARKET ANALYSIS
6.1. LUNG CANCER - GLOBAL MARKET OVERVIEW
6.2. LUNG CANCER - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. LUNG CANCER MARKET - REVENUE AND FORECASTS TO 2028 - DIAGNOSTIC
7.1. OVERVIEW
7.2. DIAGNOSTIC MARKET FORECASTS AND ANALYSIS
7.3. TEST
7.3.1. Overview
7.3.2. Test Market Forecast and Analysis
7.3.3. Spuctum cytology Market
7.3.3.1. Overview
7.3.3.2. Spuctum cytology Market Forecast and Analysis
7.3.4. Bopsy Market
7.3.4.1. Overview
7.3.4.2. Bopsy Market Forecast and Analysis
7.3.5. Imaging Market
7.3.5.1. Overview
7.3.5.2. Imaging Market Forecast and Analysis
7.3.6. Molecular Test Market
7.3.6.1. Overview
7.3.6.2. Molecular Test Market Forecast and Analysis
7.3.7. Others Market
7.3.7.1. Overview
7.3.7.2. Others Market Forecast and Analysis
7.4. TECHNOLOGY
7.4.1. Overview
7.4.2. Technology Market Forecast and Analysis
7.4.3. Fluorescent In Situ Hybridization Market
7.4.3.1. Overview
7.4.3.2. Fluorescent In Situ Hybridization Market Forecast and Analysis
7.4.4. Immunohistochemical Market
7.4.4.1. Overview
7.4.4.2. Immunohistochemical Market Forecast and Analysis
7.4.5. Others Market
7.4.5.1. Overview
7.4.5.2. Others Market Forecast and Analysis
8. LUNG CANCER MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC
8.1. OVERVIEW
8.2. THERAPEUTIC MARKET FORECASTS AND ANALYSIS
8.3. DISEASE TYPE
8.3.1. Overview
8.3.2. Disease Type Market Forecast and Analysis
8.3.3. Non-Small Cell Lung Cancer Market
8.3.3.1. Overview
8.3.3.2. Non-Small Cell Lung Cancer Market Forecast and Analysis
8.3.4. Small Cell Lung Cancer Market
8.3.4.1. Overview
8.3.4.2. Small Cell Lung Cancer Market Forecast and Analysis
8.4. MOLECULE TYPE
8.4.1. Overview
8.4.2. Molecule Type Market Forecast and Analysis
8.4.3. Small Molecules Market
8.4.3.1. Overview
8.4.3.2. Small Molecules Market Forecast and Analysis
8.4.4. Biologics Market
8.4.4.1. Overview
8.4.4.2. Biologics Market Forecast and Analysis
9. LUNG CANCER MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Lung Cancer Market Overview
9.1.2 North America Lung Cancer Market Forecasts and Analysis
9.1.3 North America Lung Cancer Market Forecasts and Analysis - By Diagnostic
9.1.4 North America Lung Cancer Market Forecasts and Analysis - By Therapeutic
9.1.5 North America Lung Cancer Market Forecasts and Analysis - By Countries
9.1.5.1 United States Lung Cancer Market
9.1.5.1.1 United States Lung Cancer Market by Diagnostic
9.1.5.1.2 United States Lung Cancer Market by Therapeutic
9.1.5.2 Canada Lung Cancer Market
9.1.5.2.1 Canada Lung Cancer Market by Diagnostic
9.1.5.2.2 Canada Lung Cancer Market by Therapeutic
9.1.5.3 Mexico Lung Cancer Market
9.1.5.3.1 Mexico Lung Cancer Market by Diagnostic
9.1.5.3.2 Mexico Lung Cancer Market by Therapeutic
9.2. EUROPE
9.2.1 Europe Lung Cancer Market Overview
9.2.2 Europe Lung Cancer Market Forecasts and Analysis
9.2.3 Europe Lung Cancer Market Forecasts and Analysis - By Diagnostic
9.2.4 Europe Lung Cancer Market Forecasts and Analysis - By Therapeutic
9.2.5 Europe Lung Cancer Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Lung Cancer Market
9.2.5.1.1 Germany Lung Cancer Market by Diagnostic
9.2.5.1.2 Germany Lung Cancer Market by Therapeutic
9.2.5.2 France Lung Cancer Market
9.2.5.2.1 France Lung Cancer Market by Diagnostic
9.2.5.2.2 France Lung Cancer Market by Therapeutic
9.2.5.3 Italy Lung Cancer Market
9.2.5.3.1 Italy Lung Cancer Market by Diagnostic
9.2.5.3.2 Italy Lung Cancer Market by Therapeutic
9.2.5.4 Spain Lung Cancer Market
9.2.5.4.1 Spain Lung Cancer Market by Diagnostic
9.2.5.4.2 Spain Lung Cancer Market by Therapeutic
9.2.5.5 United Kingdom Lung Cancer Market
9.2.5.5.1 United Kingdom Lung Cancer Market by Diagnostic
9.2.5.5.2 United Kingdom Lung Cancer Market by Therapeutic
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Lung Cancer Market Overview
9.3.2 Asia-Pacific Lung Cancer Market Forecasts and Analysis
9.3.3 Asia-Pacific Lung Cancer Market Forecasts and Analysis - By Diagnostic
9.3.4 Asia-Pacific Lung Cancer Market Forecasts and Analysis - By Therapeutic
9.3.5 Asia-Pacific Lung Cancer Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Lung Cancer Market
9.3.5.1.1 Australia Lung Cancer Market by Diagnostic
9.3.5.1.2 Australia Lung Cancer Market by Therapeutic
9.3.5.2 China Lung Cancer Market
9.3.5.2.1 China Lung Cancer Market by Diagnostic
9.3.5.2.2 China Lung Cancer Market by Therapeutic
9.3.5.3 India Lung Cancer Market
9.3.5.3.1 India Lung Cancer Market by Diagnostic
9.3.5.3.2 India Lung Cancer Market by Therapeutic
9.3.5.4 Japan Lung Cancer Market
9.3.5.4.1 Japan Lung Cancer Market by Diagnostic
9.3.5.4.2 Japan Lung Cancer Market by Therapeutic
9.3.5.5 South Korea Lung Cancer Market
9.3.5.5.1 South Korea Lung Cancer Market by Diagnostic
9.3.5.5.2 South Korea Lung Cancer Market by Therapeutic
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Lung Cancer Market Overview
9.4.2 Middle East and Africa Lung Cancer Market Forecasts and Analysis
9.4.3 Middle East and Africa Lung Cancer Market Forecasts and Analysis - By Diagnostic
9.4.4 Middle East and Africa Lung Cancer Market Forecasts and Analysis - By Therapeutic
9.4.5 Middle East and Africa Lung Cancer Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Lung Cancer Market
9.4.5.1.1 South Africa Lung Cancer Market by Diagnostic
9.4.5.1.2 South Africa Lung Cancer Market by Therapeutic
9.4.5.2 Saudi Arabia Lung Cancer Market
9.4.5.2.1 Saudi Arabia Lung Cancer Market by Diagnostic
9.4.5.2.2 Saudi Arabia Lung Cancer Market by Therapeutic
9.4.5.3 U.A.E Lung Cancer Market
9.4.5.3.1 U.A.E Lung Cancer Market by Diagnostic
9.4.5.3.2 U.A.E Lung Cancer Market by Therapeutic
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Lung Cancer Market Overview
9.5.2 South and Central America Lung Cancer Market Forecasts and Analysis
9.5.3 South and Central America Lung Cancer Market Forecasts and Analysis - By Diagnostic
9.5.4 South and Central America Lung Cancer Market Forecasts and Analysis - By Therapeutic
9.5.5 South and Central America Lung Cancer Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Lung Cancer Market
9.5.5.1.1 Brazil Lung Cancer Market by Diagnostic
9.5.5.1.2 Brazil Lung Cancer Market by Therapeutic
9.5.5.2 Argentina Lung Cancer Market
9.5.5.2.1 Argentina Lung Cancer Market by Diagnostic
9.5.5.2.2 Argentina Lung Cancer Market by Therapeutic
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LUNG CANCER MARKET, KEY COMPANY PROFILES
11.1. QUEST DIAGNOSTICS
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTRAZENECA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. GLAXOSMITHKLINE
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. AGENNIX
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ELI LILLY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BOSTON BIOMEDICAL
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. F. HOFFMANN-LA ROCHE LTD
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SIEMENS HEALTHCARE GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ONCIMMUNE HOLDINGS PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. QIAGEN
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
- Quest Diagnostics
- AstraZeneca
- GlaxoSmithKline
- Agennix
- Eli Lilly
- Boston Biomedical
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare GmbH
- Oncimmune Holdings Plc
- QIAGEN
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For